Capricor Therapeutics (CAPR) Payables (2010 - 2026)

Capricor Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• In Q1 2026, Payables fell 25.23% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (down 25.23% YoY), while the FY2025 annual figure was $1.7 million, down 49.61% from the prior year.
• Payables was $3.9 million for Q1 2026 at Capricor Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $6.8 million in Q3 2023 to a low of $1.7 million in Q4 2025.
• Historically, Payables has averaged $4.7 million across 5 years, with a median of $4.8 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Payables jumped 75.78% in 2023, then plunged 58.36% in 2025.
• A 5-year view of Payables shows it stood at $4.8 million in 2022, then grew by 29.28% to $6.3 million in 2023, then tumbled by 47.46% to $3.3 million in 2024, then sank by 49.61% to $1.7 million in 2025, then jumped by 137.37% to $3.9 million in 2026.
• The last three Payables figures came in at $3.9 million (Q1 2026), $1.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.